We market and commercialize two FDA-approved products featuring our unique and proprietary development and delivery technologies.

To our valued Tlando patients and providers:

Please be advised that as of February 1, 2024, Antares Pharma, Inc. (a wholly owned subsidiary of Halozyme Therapeutics, Inc.) is no longer marketing Tlando, due to the termination of its license agreement with Lipocine. As of this date, Verity Pharmaceuticals will market Tlando in the United States.

If you have any questions regarding Tlando, please contact Verity Pharmaceuticals using the contact information below:

For medical information inquiries and adverse event reporting: 1‑844‑VERITY‑1 (1‑844‑837‑4891)

For product complaints and all other product-related inquiries: 1-877-433-8068